Immunoprecise Antibodies Ltd
XTSX:IPA
Immunoprecise Antibodies Ltd
XTSX:IPA
Price:
6.5 CAD
0.78%
Market Closed
Updated:
May 12, 2024
EV/S
Enterprise Value to Sales
Enterprise Value to Sales
6.8
Current
6.8
Median
3.9
Industry
Lower
than median
Higher
than industry value
Enterprise Value to Sales (EV/S) ratio is a valuation multiple that compares the enterprise value (EV) of a company to its revenues. The EV/S multiple gives investors a quantifiable metric of how to value a company based on its sales while taking account of both the company's equity and debt.
EV/S
=6.8
Enterprise Value
/
129m
Revenue
19m
All Countries
| Market Cap | EV/S | ||||
|---|---|---|---|---|---|
| CA |
|
Immunoprecise Antibodies Ltd
XTSX:IPA
|
161.4m CAD | 6.8 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
229.3B USD | 5.9 | |
| US |
|
Danaher Corp
NYSE:DHR
|
187.7B USD | 4.5 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
43.9B USD | 6.6 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
42.5B USD | 3.6 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
37.9B CHF | 5.8 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
56T KRW | 14.9 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
32.5B USD | 9.1 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
26.6B USD | 8.9 | |
| IE |
|
ICON PLC
NASDAQ:ICLR
|
26.1B USD | 3.5 | |
| US |
|
Waters Corp
NYSE:WAT
|
20.8B USD | 7.7 |
EV/S Forward Multiples
Forward EV/S multiple is a version of the EV/S ratio that uses forecasted revenue for the EV/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/S
9.2
2-Years Forward
EV/S
8.8
3-Years Forward
EV/S
N/A
You don't have any saved screeners yet
